IDENTIFYING ANTIGEN CLUSTERS FOR MONITORING A GLOBAL STATE OF AN IMMUNE SYSTEM
First Claim
Patent Images
1. A method of clustering a subset of antigens of a plurality of antigens, said subset of antigens being reactive with a plurality of antibodies being derived from a plurality of patients having a disease, whereby the disease is associated with autoantibodies, the method comprising the steps of:
- (a) providing a plurality of test antigens, said test antigens being self-antigens or antigens derived from a library(b) assaying binding of said plurality of antibodies being derived from said plurality of patients with said plurality of antigens;
(c) assaying binding of a plurality of antibodies being derived from a plurality of individuals free of said disease with said plurality of antigens; and
(c) bioinformatically clustering a subset of antigens exhibiting an immune reactivity with said plurality of antibodies being derived from said plurality of patients having said disease, wherein said immune reactivity is different from that exhibited with said plurality of antibodies being derived from said individuals free of said disease.
0 Assignments
0 Petitions
Accused Products
Abstract
Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.
-
Citations
25 Claims
-
1. A method of clustering a subset of antigens of a plurality of antigens, said subset of antigens being reactive with a plurality of antibodies being derived from a plurality of patients having a disease, whereby the disease is associated with autoantibodies, the method comprising the steps of:
-
(a) providing a plurality of test antigens, said test antigens being self-antigens or antigens derived from a library (b) assaying binding of said plurality of antibodies being derived from said plurality of patients with said plurality of antigens; (c) assaying binding of a plurality of antibodies being derived from a plurality of individuals free of said disease with said plurality of antigens; and (c) bioinformatically clustering a subset of antigens exhibiting an immune reactivity with said plurality of antibodies being derived from said plurality of patients having said disease, wherein said immune reactivity is different from that exhibited with said plurality of antibodies being derived from said individuals free of said disease. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A method of diagnosing a disease of a subject, the method comprising the steps of:
-
(a) providing a plurality of test antigens; (b) clustering a subset of antigens of said plurality of test antigens, said test antigens being self-antigens or auto-antigens derived from a library, said subset of antigens being reactive with a plurality of antibodies being derived from a plurality of patients suffering from said disease by; (i) assaying binding of said plurality of antibodies being derived from said plurality of patients with said plurality of test antigens; (ii) assaying binding of a plurality of antibodies being derived from a plurality of individuals free of said disease with said plurality of test antigens; and (iii) bioinformatically clustering said subset of antigens exhibiting an immune reactivity with said plurality of antibodies being derived from said plurality of patients having said disease, wherein said immune reactivity is different from that exhibited with said plurality of antibodies being derived from said individuals free of said disease; and (c) associating or deassociating the antibodies of said subject with a cluster resulting from step (a)(iii). - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20)
-
-
21. A system for monitoring the state of the immune system of a subject suffering from a disease, the system comprising a data acquisition device and a computation device communicating therewith, said data acquisition device and said computation device being designed, constructed and configured for:
-
(a) providing a plurality of test antigens; (b) clustering a subset of antigens of said plurality of test antigens, said test antigens being self-antigens or auto-antigens derived from a library, said subset of antigens being reactive with a plurality of antibodies being derived from a plurality of patients suffering from said disease by; (i) assaying binding of said plurality of antibodies being derived from said plurality of patients with said plurality of test antigens; (ii) assaying binding of a plurality of antibodies being derived from a plurality of individuals free of said disease with said plurality of test antigens; and (iii) bioinformatically clustering said subset of antigens exhibiting an immune reactivity with said plurality of antibodies being derived from said plurality of patients having said disease, wherein said immune reactivity is different from that exhibited with said plurality of antibodies being derived from said individuals free of said disease; and (c) associating or deassociating serum of said subject with a cluster resulting from step (a)(iii). - View Dependent Claims (22, 23)
-
-
24. A method of diagnosing Type I or Type II diabetes in a subject, the method comprising, assaying binding of antibodies being derived from the subject with antigens of cluster 19 including Actin, Spectrin, Vimentin, Fibronectin, Collagen, Collagen I, Collagen IX, Peroxidase, Tyrosinase, Enolase, Ribonuclease, Human Serum Albumin, Recombinant Albumin, Fibrin, H IgM, HSP60, p277, Brain Extract, Ec27, P278, KLH and Glucocerebroside, wherein antibody binding with the antigens is indicative of Type I or Type II diabetes in the subject, wherein said binding to the antigens is greater than that of a binding of a serum from a healthy subject free of Type I diabetes to said antigens.
-
25. A method of diagnosing Type I diabetes in a subject, the method comprising, assaying binding of antibodies being derived from the subject with antigens of cluster 5 comprising Insulin and Aldolase, cluster 14 comprising Cartilage extract, cluster 26 comprising Histone II A, Lysine, Arginine, Laminin, Collagen X, Fibrinogen and Collagen VII, cluster 47 comprising Collagen X and Insulin and cluster 66 comprising Cardiolipin and Cartilage extract, wherein an antibody binding with the antigens is indicative of Type I diabetes in the subject, wherein said binding to the antigens is greater than that of a binding of a serum from a healthy subject free of Type I diabetes to said antigens.
Specification